Form D · Biotechnology

Aminex Therapeutics, Inc.

Kenmore, WA · CIK 0001613386

Offering snapshot reported Dec 5, 2025 · SEC filing

Reported sold
$15.1M
Offering amount: $30M
Investors reported
162
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Oct 25, 2022
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 5, 2025Initial$15,084,670No comparison162SEC filing
Aug 19, 2021Initial$6,298,504No comparison97SEC filing
Aug 14, 2020Initial$2,865,125No comparison96SEC filing
Jun 1, 2018Initial$8,253,117No comparison96SEC filing
Nov 12, 2014Initial$410,000No comparison3SEC filing
Jul 11, 2014Initial$1,592,697No comparison22SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-565891

Source: Form D, filed Dec 5, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Deyaa Adib Director
Mark Burns Director, Executive
Don Dyer Director
Thomas Graham Director, Executive
Stacy Hock Director
David Meeks Director
Jeff Miller Director
Jeffrey Miller Director
Donald Mowat Director
Rhonda Rhyne Director
Larry Richards Executive
John Rosling Director
James Skaggs Director
Roger Ulrich Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
6830 Ne Bothell Way Ste C139
Kenmore, WA, 98028